Position in SLXN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$3,598
+$2,937 QoQ
Shares Held
1,411
+2613.5% QoQ
Ownership
0.025%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#2
of 6 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SLXN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026UBS Group AG holds $8,789,672,124 across 561 Biotechnology names. SLXN ranks #479 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
5,450,825 | $1,020,369,609 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
17,466,641 | $618,144,423 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
3,399,221 | $416,676,508 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
712,259 | $353,800,411 | |
| 5 | MRNA |
Moderna, Inc.
|
4,463,211 | $312,558,664 | |
| 6 | INSM |
INSMED Inc
|
2,584,446 | $275,553,630 | |
| 7 | ABVX |
Abivax S.A.
|
1,844,918 | $245,853,771 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
401,708 | $215,697,109 |
All Filings in SLXN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,598 | 1,411 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $661 | 517 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $3,246 | 1,691 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $2,352 | 692 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $88,498 | 109,257 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $80,161 | 72,874 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $29,856 | 14,854 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $7,905 | 15,059 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||